Company: EUDAW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001493152-25-011729
Chunk: 23

Company: EUDA Health Holdings Ltd
Filing Date: 2025-08-08
Form: 424B5
Chunk 23
---
652,926 | ) |
| Accumulated other comprehensive loss                                                                              |     |                      |    (259,532 | ) |     |             |          - |   |     |                   |    (259,532 | ) |
| Total shareholders’ deficit                                                                                       |     |                      |  (2,553,059 | ) |     |             |  7,447,500 |   |     |                   |   4,894,441 |   |
| Noncontrolling interest                                                                                           |     |                      |     (19,009 | ) |     |             |          - |   |     |                   |           - |   |
| Total shareholders’ deficit                                                                                       |     |                      |  (2,572,068 | ) |     |             |  7,447,500 |   |     |                   |   4,894,441 |   |

You should read this capitalization table in conjunction with Use of Proceeds, the financial statements and notes thereto and other financial information incorporated by reference into this prospectus and any prospectus supplement. Our historical results do not necessarily indicate our expected results for any future periods.

| S-16 |

<div align='center'>PLAN OF DISTRIBUTION/SELLING SHAREHOLDER</div>

We are offering, in a registered direct offering to Indigo Capital LP, an accredited investor (the “Investor”), one or more convertible promissory notes in amounts not to exceed US$10,000,000 principal amount, in the aggregate, of convertible notes (the “Convertible Notes”). Each Convertible Note, if issued pursuant to a put request in an amount requested by the Company and accepted by the Investor (each, an “Advance”), shall be convertible into newly-issued ordinary shares, no par value each, of the Company (“Ordinary Shares”) at a conversion rate equal to 85% of the price of the Company’s Ordinary Shares on Nasdaq on the date the Investor submits a conversion notice to the Company (the “Conversion Notice”). The Advances relating to each Note shall be the purchase price of each Convertible Note and shall be equal to ninety percent (90.00%) of the principal amount of the Convertible Note.

The Convertible Note and Ordinary Shares issuable thereunder, are offered directly to the Investor without a placement agent, underwriter, broker or dealer. The Ordinary Shares issuable upon conversion of the Convertible Notes will be issued at 85% of the closing price of the Company’s Ordinary Shares on